Olof Elvstam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olof Elvstam has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Christina Carlander
Department of Medicine Huddinge, Karolinska Institutet , Stockholm
5 shared publications Johanna Brännström
Unit of Infectious Diseases and Dermatology, Department of Medicine Huddinge, Karolinska Institute, Huddinge, Sweden
5 shared publicationsMagnus Gisslén
Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
5 shared publicationsPer Björkman
Department of Translational Medicine, Lund University , Malmö , Sweden
5 shared publicationsCarl Johan Treutiger
Department of Infectious Diseases/Venhälsan, South General Hospital, Stockholm
4 shared publicationsGaetano Marrone
Department of Infectious Diseases and Clinical Virology, Karolinska University Hospital , Stockholm , Sweden
4 shared publications
Latest Publications
- Open Access
Comparison of an ensemble machine learning model to a Cox regression model to predict colorectal cancer risk among people with HIV using retrospective nationwide cohort data in Sweden: a study protocol
Introduction: There are currently no colorectal cancer (CRC) screening recommendations specifically outlined for people with HIV (PWH). Screening measures used for people without HIV (PWoH) have been previously discussed as sufficient for use among PWH, despite observations of higher CRC prevalence and CRC reportedly appearing at earlier ages among PWH in comparison to PWoH. Machine learning (ML) methods are regarded as robust approaches that may enhance predictive performance, particularly in the context of complex or high-dimensional data. This study aims to develop an ensemble ML model to predict CRC risk in PWH using comprehensive nationwide datasets. The model’s predictive performance will be evaluated and compared with a baseline Cox proportional regression model. The better-performing method will be implemented to develop a CRC risk prediction model with the aim of personalising screening recommendations for PWH. Methods and analysis: The study population will include all PWH and PWoH born between 1940 and 2008, aged 18 or older and living in Sweden sometime between 1983 and 2024. The study population will be linked to six nationwide demographic and healthcare registers. Follow-up will continue until the first incident of CRC, emigration or death. The outcome of interest is CRC. PWH will be matched to negative controls 1:10. A Cox regression analysis will be completed first, and the results will be used as a baseline comparison to the ensemble ML results. A range of ML methods will be used to develop the ensemble model using stacking. Ethics and dissemination: This study has ethical approval from the Regional Ethical Committee in Sweden (Dnr: 2024-04185-02, 2024-06783-02, 2023-00191-01, 2022-02897-02, 2022-05624-01, 2018/11-31/2). Given that the study is retrospective and register-based, using only pseudonymised data, there are minimal physical, psychological or privacy risks to included individuals. All results will be presented at the population level with no possibility of identification. The results of this study will be submitted for publication in a peer-reviewed journal.
Open AccessComparison of an ensemble machine learning model to a Cox regression model to predict colorectal cancer risk among people with HIV using retrospective nationwide cohort data in Sweden: a study protocol
Introduction: There are currently no colorectal cancer (CRC) screening recommendations specifically outlined for people with HIV (PWH). Screening measures used for people without HIV (PWoH) have been previously discussed as sufficient for use among PWH, despite observations of higher CRC prevalence and CRC reportedly appearing at earlier ages among PWH in comparison to PWoH. Machine learning (ML) methods are regarded as robust approaches that may enhance predictive performance, particularly in the context of complex or high-dimensional data. This study aims to develop an ensemble ML model to predict CRC risk in PWH using comprehensive nationwide datasets. The model’s predictive performance will be evaluated and compared with a baseline Cox proportional regression model. The better-performing method will be implemented to develop a CRC risk prediction model with the aim of personalising screening recommendations for PWH. Methods and analysis: The study population will include all PWH and PWoH born between 1940 and 2008, aged 18 or older and living in Sweden sometime between 1983 and 2024. The study population will be linked to six nationwide demographic and healthcare registers. Follow-up will continue until the first incident of CRC, emigration or death. The outcome of interest is CRC. PWH will be matched to negative controls 1:10. A Cox regression analysis will be completed first, and the results will be used as a baseline comparison to the ensemble ML results. A range of ML methods will be used to develop the ensemble model using stacking. Ethics and dissemination: This study has ethical approval from the Regional Ethical Committee in Sweden (Dnr: 2024-04185-02, 2024-06783-02, 2023-00191-01, 2022-02897-02, 2022-05624-01, 2018/11-31/2). Given that the study is retrospective and register-based, using only pseudonymised data, there are minimal physical, psychological or privacy risks to included individuals. All results will be presented at the population level with no possibility of identification. The results of this study will be submitted for publication in a peer-reviewed journal.
- 2 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (5) , e1059-e1060
Renal Risk and Creatinine Elevation in People With HIV—Broadening the Perspective
- 2 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (5) , e1059-e1060
Renal Risk and Creatinine Elevation in People With HIV—Broadening the Perspective
- Open Access
- 18 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , e1252-e1261
Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024
Background: Type 2 diabetes mellitus (T2DM) is common among people with HIV (PWH), although studies comparing T2DM-related complications in people with and without HIV (PWoH) remain limited. This was assessed using data from the Cohort Study on Morbidity and HIV in Sweden (COSMOHS). Methods: Nationwide study including Swedish residents born 1930–2006, diagnosed with T2DM between 2010 and 2019, followed until 31 December 2024, using 7 national registers including national HIV and diabetes registers. Follow-up began at T2DM diagnosis. Outcomes included renal events, cardiovascular events, and all-cause mortality. Cox proportional regression estimated hazard ratios (adjHRs) by HIV status, stratified by propensity score quintiles of age, sex, migrant status, comorbidities, and socioeconomics. Results: 350 PWH and 311 668 PWoH were included, with similar median follow-up time (PWH, 7.8 years; PWoH, 8.8 years). PWH had higher renal risk than PWoH (major adverse kidney event: adjHR, 2.04; 95% CI, 1.57-2.65) but no significantly increased cardiovascular risk (major adverse cardiovascular event: adjHR, 1.18; 95% CI, .87–1.60) or all-cause mortality. Findings were consistent across sensitivity analyses, including competing-risk models for death and excluding PWH receiving tenofovir disoproxil fumarate at baseline. Accounting for the benign plasma/serum-creatinine increase associated with bictegravir, cobicistat, dolutegravir, and rilpivirine, the increased renal risk remained, although not statistically significant. The renal risk was most prominent in PWH with BMI ≥30 kg/m2. Conclusions: In this nationwide cohort, PWH with T2DM exhibited higher risk of renal complications than PWoH, indicating enhanced renal monitoring may be warranted. Further research should investigate underlying mechanisms, including antiretroviral therapy, to guide clinical management.
- 18 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , e1252-e1261
Open AccessRenal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024
Background: Type 2 diabetes mellitus (T2DM) is common among people with HIV (PWH), although studies comparing T2DM-related complications in people with and without HIV (PWoH) remain limited. This was assessed using data from the Cohort Study on Morbidity and HIV in Sweden (COSMOHS). Methods: Nationwide study including Swedish residents born 1930–2006, diagnosed with T2DM between 2010 and 2019, followed until 31 December 2024, using 7 national registers including national HIV and diabetes registers. Follow-up began at T2DM diagnosis. Outcomes included renal events, cardiovascular events, and all-cause mortality. Cox proportional regression estimated hazard ratios (adjHRs) by HIV status, stratified by propensity score quintiles of age, sex, migrant status, comorbidities, and socioeconomics. Results: 350 PWH and 311 668 PWoH were included, with similar median follow-up time (PWH, 7.8 years; PWoH, 8.8 years). PWH had higher renal risk than PWoH (major adverse kidney event: adjHR, 2.04; 95% CI, 1.57-2.65) but no significantly increased cardiovascular risk (major adverse cardiovascular event: adjHR, 1.18; 95% CI, .87–1.60) or all-cause mortality. Findings were consistent across sensitivity analyses, including competing-risk models for death and excluding PWH receiving tenofovir disoproxil fumarate at baseline. Accounting for the benign plasma/serum-creatinine increase associated with bictegravir, cobicistat, dolutegravir, and rilpivirine, the increased renal risk remained, although not statistically significant. The renal risk was most prominent in PWH with BMI ≥30 kg/m2. Conclusions: In this nationwide cohort, PWH with T2DM exhibited higher risk of renal complications than PWoH, indicating enhanced renal monitoring may be warranted. Further research should investigate underlying mechanisms, including antiretroviral therapy, to guide clinical management.
- Open Access
- 31 March 2026
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 61, 99-105
Number of risk factors versus infection after transrectal prostate biopsy: a nationwide population-based study
Objective: It is unknown how risk factors for infection after transrectal prostate biopsy interact. We designed a study to evaluate this. Methods: We identified biopsy procedures from 2006 to 2020 in the Swedish nationwide database PCBaSe. Primary outcome was post-biopsy infection, defined as a dispensed prescription of a urinary tract antibiotic and secondary outcome was inpatient care for infection both within 30 days. Risk factors were age, diabetes, medical treatment of lower urinary tract symptoms (LUTSs), prostate enlargement, immunosuppressives, corticosteroids, and defined antibiotic exposure during the past 1–12 months. When analysing risk in men with several risk factors clinically related factors were grouped as urinary tract infection (UTI)-antibiotics, treatment of LUTS, immunosuppressives including corticosteroids, and diabetes. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CI). Results: A total of 139,056 transrectal prostate biopsy procedures were analysed. The grouped risk factors were significantly associated with post-biopsy infection (multivariable ORs: 1.22–1.72). Infection increased with number of risk factors; none: 4.0% (95% CI: 3.8–4.1), one: 6% (95% CI: 5.9–6.4), two: 10% (95% CI: 9.3–11), and three or four: 12% (95% CI: 9.8–14); inpatient care increased from 2.0% (95% CI: 1.9–2.1) to 3.1% (95% CI: 2.2–4.4). Conclusion: Infection risk after transrectal prostate biopsy incrementally increases with the number of risk factors.Clinical Implications: The transrectal biopsy route should be used with caution for patients with several risk factors for post-biopsy infections. Patient Summary: Diabetes, urinary symptoms, previous urinary infection, and immune suppressing medication increase the risk of infection after a prostate biopsy through the rectum. Patients with many of these conditions have a particularly high risk. What does the study add? We used nationwide register data to estimate the infection risk after transrectal prostate biopsy by the number of these risk factors: diabetes, medical treatment of lower urinary tract symptoms, immunosuppressives including corticosteroids, and use of urinary tract antibiotics the past year. The risk incrementally increased from 4.0% in men with no risk factor to 12% in those with 3 or 4. Take Home Message: Infection after transrectal prostate biopsy increases with number of risk factors: diabetes, medical treatment of lower urinary tract symptoms, immunosuppressives including corticosteroids, and use of urinary tract antibiotics the past year, from 4.0% (none) to 12% (3 or 4).
- 31 March 2026
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 61, 99-105
Open AccessNumber of risk factors versus infection after transrectal prostate biopsy: a nationwide population-based study
Objective: It is unknown how risk factors for infection after transrectal prostate biopsy interact. We designed a study to evaluate this. Methods: We identified biopsy procedures from 2006 to 2020 in the Swedish nationwide database PCBaSe. Primary outcome was post-biopsy infection, defined as a dispensed prescription of a urinary tract antibiotic and secondary outcome was inpatient care for infection both within 30 days. Risk factors were age, diabetes, medical treatment of lower urinary tract symptoms (LUTSs), prostate enlargement, immunosuppressives, corticosteroids, and defined antibiotic exposure during the past 1–12 months. When analysing risk in men with several risk factors clinically related factors were grouped as urinary tract infection (UTI)-antibiotics, treatment of LUTS, immunosuppressives including corticosteroids, and diabetes. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CI). Results: A total of 139,056 transrectal prostate biopsy procedures were analysed. The grouped risk factors were significantly associated with post-biopsy infection (multivariable ORs: 1.22–1.72). Infection increased with number of risk factors; none: 4.0% (95% CI: 3.8–4.1), one: 6% (95% CI: 5.9–6.4), two: 10% (95% CI: 9.3–11), and three or four: 12% (95% CI: 9.8–14); inpatient care increased from 2.0% (95% CI: 1.9–2.1) to 3.1% (95% CI: 2.2–4.4). Conclusion: Infection risk after transrectal prostate biopsy incrementally increases with the number of risk factors.Clinical Implications: The transrectal biopsy route should be used with caution for patients with several risk factors for post-biopsy infections. Patient Summary: Diabetes, urinary symptoms, previous urinary infection, and immune suppressing medication increase the risk of infection after a prostate biopsy through the rectum. Patients with many of these conditions have a particularly high risk. What does the study add? We used nationwide register data to estimate the infection risk after transrectal prostate biopsy by the number of these risk factors: diabetes, medical treatment of lower urinary tract symptoms, immunosuppressives including corticosteroids, and use of urinary tract antibiotics the past year. The risk incrementally increased from 4.0% in men with no risk factor to 12% in those with 3 or 4. Take Home Message: Infection after transrectal prostate biopsy increases with number of risk factors: diabetes, medical treatment of lower urinary tract symptoms, immunosuppressives including corticosteroids, and use of urinary tract antibiotics the past year, from 4.0% (none) to 12% (3 or 4).
- Open Access
- 12 March 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (6) , 945-958
Late diagnosis of HIV persists in Sweden: Differing social determinants among migrant and non‐migrant people with HIV
Objective: To examine temporal changes in late diagnosis of HIV (LD) among migrant and non‐migrant people with HIV in Sweden 2003–2023 and to assess demographic and socioeconomic risk factors for LD in these two populations. Methods: People with HIV diagnosed with HIV‐1 in Sweden 2003–2023 were included ( n = 6278). LD was defined as a first CD4+ T‐cell count n = 2778). Data were obtained from Swedish national registries. Results: The absolute incidence of total and late HIV diagnoses decreased over the study period, whereas the annual proportion of LD varied between 46% and 60% and trended upwards. LD occurred in 41% of non‐migrant people with HIV and 58% of migrant people with HIV. Among non‐migrant people with HIV, having an upper secondary education or less was associated with LD compared to post‐secondary education, as was male sex with heterosexual HIV acquisition and higher age. For migrant people with HIV, neither lower education nor income was statistically significantly associated with LD. Instead, higher age, certain birth regions, heterosexual acquisition and male sex with acquisition through injection drug use were associated with LD. Conclusions: LD declined in absolute terms yet constituted a high and increasing proportion of new HIV cases in Sweden 2003–2023, with differing sociodemographic determinants by migrant status.
- 12 March 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (6) , 945-958
Open AccessLate diagnosis of HIV persists in Sweden: Differing social determinants among migrant and non‐migrant people with HIV
Objective: To examine temporal changes in late diagnosis of HIV (LD) among migrant and non‐migrant people with HIV in Sweden 2003–2023 and to assess demographic and socioeconomic risk factors for LD in these two populations. Methods: People with HIV diagnosed with HIV‐1 in Sweden 2003–2023 were included ( n = 6278). LD was defined as a first CD4+ T‐cell count n = 2778). Data were obtained from Swedish national registries. Results: The absolute incidence of total and late HIV diagnoses decreased over the study period, whereas the annual proportion of LD varied between 46% and 60% and trended upwards. LD occurred in 41% of non‐migrant people with HIV and 58% of migrant people with HIV. Among non‐migrant people with HIV, having an upper secondary education or less was associated with LD compared to post‐secondary education, as was male sex with heterosexual HIV acquisition and higher age. For migrant people with HIV, neither lower education nor income was statistically significantly associated with LD. Instead, higher age, certain birth regions, heterosexual acquisition and male sex with acquisition through injection drug use were associated with LD. Conclusions: LD declined in absolute terms yet constituted a high and increasing proportion of new HIV cases in Sweden 2003–2023, with differing sociodemographic determinants by migrant status.
- Open Access
- 12 June 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (8) , 1311-1316
Factors mediating and associated with immunological response in women living with HIV in Sweden: A nationwide register‐based study
Introduction: Women remain underrepresented in studies on immunological response (IR) among virally suppressed people living with HIV. Despite receiving antiretroviral therapy (ART) some individuals do not attain an IR, increasing their risk of non‐AIDS morbidity and mortality. This nationwide study investigated biomedical and social factors associated with IR among women with HIV in Sweden. Methods: We conducted a register‐based cohort study using the Swedish National HIV Registry (InfCareHIV). Virally suppressed women diagnosed with HIV between 2000 and 2020, ≥18 years old were included. Included women were observed for 2 years after ART initiation. The associations between IR and clinical and social determinants were investigated using logistic regression. Results: There were 841 women included in the final model, of whom 90% ( n = 739, 95% CI: 0.88–0.92) had an IR after a 2‐year follow‐up. Mean age was 37 years at inclusion, and 52% ( n = 439) were born in a sub‐Saharan African country. A significant interaction between baseline HIV viral load and HIV acquisition mode was observed. Higher baseline HIV viral load (≥100 000 copies/mL) increased the odds of IR (adjOR 1.81, 95% CI: 0.96–3.41), except among women acquiring HIV via intravenous drug use (IDU), where this association was strongly attenuated (adjOR: 0.03; 95% CI: 0.01–0.35). Baseline CD4, ART experience and age showed no significant associations. Conclusions: The relationship between higher baseline HIV viral load and improved IR differed by HIV acquisition mode, suggesting the importance of tailored interventions addressing social determinants and immune activation. This potential interaction needs to be validated in future studies, also including sex‐specific variables.
- 12 June 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (8) , 1311-1316
Open AccessFactors mediating and associated with immunological response in women living with HIV in Sweden: A nationwide register‐based study
Introduction: Women remain underrepresented in studies on immunological response (IR) among virally suppressed people living with HIV. Despite receiving antiretroviral therapy (ART) some individuals do not attain an IR, increasing their risk of non‐AIDS morbidity and mortality. This nationwide study investigated biomedical and social factors associated with IR among women with HIV in Sweden. Methods: We conducted a register‐based cohort study using the Swedish National HIV Registry (InfCareHIV). Virally suppressed women diagnosed with HIV between 2000 and 2020, ≥18 years old were included. Included women were observed for 2 years after ART initiation. The associations between IR and clinical and social determinants were investigated using logistic regression. Results: There were 841 women included in the final model, of whom 90% ( n = 739, 95% CI: 0.88–0.92) had an IR after a 2‐year follow‐up. Mean age was 37 years at inclusion, and 52% ( n = 439) were born in a sub‐Saharan African country. A significant interaction between baseline HIV viral load and HIV acquisition mode was observed. Higher baseline HIV viral load (≥100 000 copies/mL) increased the odds of IR (adjOR 1.81, 95% CI: 0.96–3.41), except among women acquiring HIV via intravenous drug use (IDU), where this association was strongly attenuated (adjOR: 0.03; 95% CI: 0.01–0.35). Baseline CD4, ART experience and age showed no significant associations. Conclusions: The relationship between higher baseline HIV viral load and improved IR differed by HIV acquisition mode, suggesting the importance of tailored interventions addressing social determinants and immune activation. This potential interaction needs to be validated in future studies, also including sex‐specific variables.
- Open Access
- 13 February 2025
- Published by Taylor & Francis in Global Health Action
- Vol. 18 (1) , 2464342
Low-level viremia in people with HIV in Ethiopia is associated with subsequent lack of viral suppression and attrition from care
Low-level viremia during antiretroviral therapy (ART) has been associated with inferior outcomes, but knowledge on the impact of low-level viremia in the current era of dolutegravir-based ART in low-income countries is limited. To investigate whether low-level viremia predicts virologic non-suppression and attrition from care in people with HIV receiving ART in Ethiopia. We included people receiving ART at public health facilities in an urban area in central Ethiopia and categorized persons with ≥1 available viral load 2019–2020 as having either suppression (1,000 copies/mL were excluded. We used multivariable logistic regression adjusted for age, sex, ART regimen, type of health facility, and duration of ART to analyze the associations between viremia category and incidence of unsuppressed viral load (>1,000 copies/mL) and attrition from care (death or loss to follow-up) during 3 years of follow-up. Among 12,165 participants, the median age was 44 years, 64.2% were female, and 89.1% received tenofovir/lamivudine/dolutegravir. Of the study population, 11,959 (98.3%) had suppression and 206 (1.7%) had low-level viremia. Over 3 years of follow-up, 2.2% of participants with suppression and 11.3% with low-level viremia had unsuppressed viral load. Low-level viremia was associated with both unsuppressed viremia (adjusted odds ratio [aOR], 3.7; 95% confidence interval [CI], 2.2–6.2) and attrition (aOR, 3.4; 95% CI, 1.7–6.6). Among Ethiopian people with HIV receiving ART, low-level viremia predicted subsequent virologic non-suppression and attrition from care, supporting current recommendations for heightened attention to low-level viremia in ART recipients.
- 13 February 2025
- Published by Taylor & Francis in Global Health Action
- Vol. 18 (1) , 2464342
Open AccessLow-level viremia in people with HIV in Ethiopia is associated with subsequent lack of viral suppression and attrition from care
Low-level viremia during antiretroviral therapy (ART) has been associated with inferior outcomes, but knowledge on the impact of low-level viremia in the current era of dolutegravir-based ART in low-income countries is limited. To investigate whether low-level viremia predicts virologic non-suppression and attrition from care in people with HIV receiving ART in Ethiopia. We included people receiving ART at public health facilities in an urban area in central Ethiopia and categorized persons with ≥1 available viral load 2019–2020 as having either suppression (1,000 copies/mL were excluded. We used multivariable logistic regression adjusted for age, sex, ART regimen, type of health facility, and duration of ART to analyze the associations between viremia category and incidence of unsuppressed viral load (>1,000 copies/mL) and attrition from care (death or loss to follow-up) during 3 years of follow-up. Among 12,165 participants, the median age was 44 years, 64.2% were female, and 89.1% received tenofovir/lamivudine/dolutegravir. Of the study population, 11,959 (98.3%) had suppression and 206 (1.7%) had low-level viremia. Over 3 years of follow-up, 2.2% of participants with suppression and 11.3% with low-level viremia had unsuppressed viral load. Low-level viremia was associated with both unsuppressed viremia (adjusted odds ratio [aOR], 3.7; 95% confidence interval [CI], 2.2–6.2) and attrition (aOR, 3.4; 95% CI, 1.7–6.6). Among Ethiopian people with HIV receiving ART, low-level viremia predicted subsequent virologic non-suppression and attrition from care, supporting current recommendations for heightened attention to low-level viremia in ART recipients.
- Open Access
- 13 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf016
Viremia Does Not Independently Predict Cardiovascular Disease in People With HIV: A RESPOND Cohort Study
Background: HIV viremia has been considered a cardiovascular disease (CVD) risk factor, but many studies have had insufficient data on potential confounders. We explored the association between viremia and CVD after adjusting for established risk factors and analyzed whether consideration of viremia would improve CVD prediction. Methods: Adults from RESPOND were followed from the first date with available data until the first of rigorously defined CVD, loss to follow-up, death, or administrative censoring. We first analyzed the associations between 6 measures of viremia (time-updated, before antiretroviral therapy [ART], viremia category, and measures of cumulative viremia) and CVD after adjusting for the variables in the D:A:D CVD score (age, sex/gender, smoking, family history, diabetes, recent abacavir, CD4 count, blood pressure, cholesterol, high-density lipoprotein, cumulative use of stavudine, didanosine, indinavir, lopinavir, and darunavir). We subsequently compared predictive performance with and without viremia in 5-fold internal cross-validation. Results: A total of 547 events were observed in 17 497 persons (median follow-up, 6.8 years). Although some viremia variables were associated with CVD in univariable analyses, there were no statistically significant associations after adjusting for potential confounders, neither for measures of current viral load, pre-ART viral load, highest viremia category during ART, nor cumulative viremia (modeled both as total cumulative viremia, cumulative viremia during ART, and recent cumulative viremia). Consistently, none of the viremia variables improved prediction capacity. Conclusions: In this large international cohort, HIV viremia was not associated with CVD when adjusting for established risk factors. Our results did not show viremia to be predictive of CVD among people with HIV.
- 13 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf016
Open AccessViremia Does Not Independently Predict Cardiovascular Disease in People With HIV: A RESPOND Cohort Study
Background: HIV viremia has been considered a cardiovascular disease (CVD) risk factor, but many studies have had insufficient data on potential confounders. We explored the association between viremia and CVD after adjusting for established risk factors and analyzed whether consideration of viremia would improve CVD prediction. Methods: Adults from RESPOND were followed from the first date with available data until the first of rigorously defined CVD, loss to follow-up, death, or administrative censoring. We first analyzed the associations between 6 measures of viremia (time-updated, before antiretroviral therapy [ART], viremia category, and measures of cumulative viremia) and CVD after adjusting for the variables in the D:A:D CVD score (age, sex/gender, smoking, family history, diabetes, recent abacavir, CD4 count, blood pressure, cholesterol, high-density lipoprotein, cumulative use of stavudine, didanosine, indinavir, lopinavir, and darunavir). We subsequently compared predictive performance with and without viremia in 5-fold internal cross-validation. Results: A total of 547 events were observed in 17 497 persons (median follow-up, 6.8 years). Although some viremia variables were associated with CVD in univariable analyses, there were no statistically significant associations after adjusting for potential confounders, neither for measures of current viral load, pre-ART viral load, highest viremia category during ART, nor cumulative viremia (modeled both as total cumulative viremia, cumulative viremia during ART, and recent cumulative viremia). Consistently, none of the viremia variables improved prediction capacity. Conclusions: In this large international cohort, HIV viremia was not associated with CVD when adjusting for established risk factors. Our results did not show viremia to be predictive of CVD among people with HIV.
- Open Access
- 18 March 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-8
Difficult-to-treat HIV in Sweden: a cross-sectional study
Our aim was to examine the prevalence and characteristics of difficult-to-treat HIV in the current Swedish HIV cohort and to compare treatment outcomes between people with difficult and non-difficult-to-treat HIV. In this cross-sectional analysis of the Swedish HIV cohort, we identified all people with HIV currently in active care in 2023 from the national register InfCareHIV. We defined five categories of difficult-to-treat HIV: 1) advanced resistance, 2) four-drug regimen, 3) salvage therapy, 4) virologic failure within the past 12 months, and 5) ≥ 2 regimen switches following virologic failure since 2008. People classified as having difficult-to-treat HIV were compared with non-difficult for background characteristics as well as treatment outcomes (viral suppression and self-reported physical and psychological health). Nine percent of the Swedish HIV cohort in 2023 (n = 8531) met at least one criterion for difficult-to-treat HIV. Most of them had ≥ 2 regimen switches (6%), and the other categories of difficult-to-treat HIV were rare (1–2% of the entire cohort). Compared with non-difficult, people with difficult-to-treat HIV were older, had an earlier first year of positive HIV test and lower CD4 counts, and were more often female. The viral suppression rate among people with difficult-to-treat HIV was 84% compared with 95% for non-difficult (p = 0.001). People with difficult-to-treat HIV reported worse physical (but not psychological) health, and this remained statistically significant after adjustment for age, sex, and transmission group. Although 9% of the HIV cohort in Sweden in 2023 were classified as having difficult-to-treat HIV, a large proportion of these were virally suppressed, and challenges such as advanced resistance and need for salvage therapy are rare in the current Swedish cohort.
- 18 March 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-8
Open AccessDifficult-to-treat HIV in Sweden: a cross-sectional study
Our aim was to examine the prevalence and characteristics of difficult-to-treat HIV in the current Swedish HIV cohort and to compare treatment outcomes between people with difficult and non-difficult-to-treat HIV. In this cross-sectional analysis of the Swedish HIV cohort, we identified all people with HIV currently in active care in 2023 from the national register InfCareHIV. We defined five categories of difficult-to-treat HIV: 1) advanced resistance, 2) four-drug regimen, 3) salvage therapy, 4) virologic failure within the past 12 months, and 5) ≥ 2 regimen switches following virologic failure since 2008. People classified as having difficult-to-treat HIV were compared with non-difficult for background characteristics as well as treatment outcomes (viral suppression and self-reported physical and psychological health). Nine percent of the Swedish HIV cohort in 2023 (n = 8531) met at least one criterion for difficult-to-treat HIV. Most of them had ≥ 2 regimen switches (6%), and the other categories of difficult-to-treat HIV were rare (1–2% of the entire cohort). Compared with non-difficult, people with difficult-to-treat HIV were older, had an earlier first year of positive HIV test and lower CD4 counts, and were more often female. The viral suppression rate among people with difficult-to-treat HIV was 84% compared with 95% for non-difficult (p = 0.001). People with difficult-to-treat HIV reported worse physical (but not psychological) health, and this remained statistically significant after adjustment for age, sex, and transmission group. Although 9% of the HIV cohort in Sweden in 2023 were classified as having difficult-to-treat HIV, a large proportion of these were virally suppressed, and challenges such as advanced resistance and need for salvage therapy are rare in the current Swedish cohort.
- Open Access
- 30 November 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (48) , 2300224
The molecular epidemiology of HIV-1 in Sweden 1996 to 2022, and the influence of migration from Ukraine
Background: The global distribution of HIV-1 subtypes is evolving, which is reflected in the Swedish HIV cohort. The subtype HIV-1A6, which may be prone to developing resistance to cabotegravir, is the most common subtype in Ukraine. Aim: We aimed to examine trends in HIV-1 subtype distribution in Sweden, with a special focus on HIV-1A6, and to describe the virology, demography and treatment of Ukrainian people living with HIV (PLWH) who migrated to Sweden in 2022. Methods: Data about PLWH in Sweden are included in a national database (InfCareHIV). We used the online tool COMET to establish HIV-1 subtypes and the Stanford database to define drug resistance mutations. We investigated the relation between virological characteristics and demographic data. Results: The early epidemic was predominated by HIV-1 subtype B infections in people born in Sweden. After 1990, the majority of new PLWH in Sweden were PLWH migrating to Sweden, resulting in an increasingly diverse epidemic. In 2022, HIV-1A6 had become the sixth most common subtype in Sweden and 98 of the 431 new PLWH that were registered in Sweden came from Ukraine. We detected HIV RNA in plasma of 32 Ukrainian patients (34%), of whom 17 were previously undiagnosed, 10 had interrupted therapy and five were previously diagnosed but not treated. We found HIV-1A6 in 23 of 24 sequenced patients. Conclusion: The molecular HIV epidemiology in Sweden continues to diversify and PLWH unaware of their HIV status and predominance of HIV-1A6 should be considered when arranging care directed at PLWH from Ukraine.
- 30 November 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (48) , 2300224
Open AccessThe molecular epidemiology of HIV-1 in Sweden 1996 to 2022, and the influence of migration from Ukraine
Background: The global distribution of HIV-1 subtypes is evolving, which is reflected in the Swedish HIV cohort. The subtype HIV-1A6, which may be prone to developing resistance to cabotegravir, is the most common subtype in Ukraine. Aim: We aimed to examine trends in HIV-1 subtype distribution in Sweden, with a special focus on HIV-1A6, and to describe the virology, demography and treatment of Ukrainian people living with HIV (PLWH) who migrated to Sweden in 2022. Methods: Data about PLWH in Sweden are included in a national database (InfCareHIV). We used the online tool COMET to establish HIV-1 subtypes and the Stanford database to define drug resistance mutations. We investigated the relation between virological characteristics and demographic data. Results: The early epidemic was predominated by HIV-1 subtype B infections in people born in Sweden. After 1990, the majority of new PLWH in Sweden were PLWH migrating to Sweden, resulting in an increasingly diverse epidemic. In 2022, HIV-1A6 had become the sixth most common subtype in Sweden and 98 of the 431 new PLWH that were registered in Sweden came from Ukraine. We detected HIV RNA in plasma of 32 Ukrainian patients (34%), of whom 17 were previously undiagnosed, 10 had interrupted therapy and five were previously diagnosed but not treated. We found HIV-1A6 in 23 of 24 sequenced patients. Conclusion: The molecular HIV epidemiology in Sweden continues to diversify and PLWH unaware of their HIV status and predominance of HIV-1A6 should be considered when arranging care directed at PLWH from Ukraine.